BioCardia, headquartered in San Carlos, CA, is a privately-held company developing regenerative biologic therapies to treat cardiovascular disease. The Company's products include the Helix transendocardial delivery system and the Morph steerable guide and sheath catheter portfolio. BioCardia also partners with other biotherapeutic companies to provide its Helix systems and clinical support to their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction.
BioCardia has filed 42 patents.
Stem cells, Transcription factors, Developmental biology, Cell biology, Clusters of differentiation
Stem cells, Transcription factors, Developmental biology, Cell biology, Clusters of differentiation
Latest BioCardia News
Sep 13, 2023
BCDAW The Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter) ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On September 6, 2023, BioCardia, Inc. (the "Company") received a written notice (the "Notice") from the Nasdaq Listing Qualifications staff of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, for the last 30 consecutive business days, the Market Value of Listed Securities, as defined by Nasdaq ("MVLS"), had been below the $35 million minimum requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the "MVLS Requirement"). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has been provided an initial period of 180 calendar days, or until March 4, 2024, to regain compliance with the MVLS Requirement. The Notice states that the Nasdaq staff will provide written notification that the Company has achieved compliance with Rule 5550(b)(2) if, at any time before March 4, 2024, the Company's MVLS closes at $35 million or more for a minimum of ten consecutive business days. The Notice has no immediate effect on the listing or trading of the Company's common stock. If compliance is not achieved by March 4, 2024, the Company expects that Nasdaq will provide written notification to the Company that its securities are subject to delisting. The Company intends to actively monitor its MVLS and consider its available options to regain compliance with the MVLS Requirement, which may include applying for an extension of the compliance period beyond March 4, 2024. If the Company does not regain compliance within the allotted compliance periods, including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company's common stock will be subject to delisting. The Company would then be entitled to appeal that determination to a Nasdaq hearings panel. There can be no assurance that the Company will regain compliance with the MVLS Requirement during the 180-day compliance period ending March 4, 2024, secure an extension of the compliance period beyond March 4, 2024 or maintain compliance with any other Nasdaq listing requirements. Forward-looking statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not purely historical regarding the Company's or its management's intentions, beliefs, expectations and strategies for the future, including statements regarding the Company's ability to regain compliance with the MVLS Requirement, the Company's intentions to actively monitor its MVLS, and the Company's plans to consider implementing available options to regain compliance with the MVLS Requirement. All forward-looking statements included in this Current Report on Form 8-K are made as of the date of this report, based on information currently available to the Company, deal with future events, are subject to various risks and uncertainties, including the risk that the Company may not meet the MVLS Requirement by March 4, 2024 or in the future, the risk that the Company may not otherwise meet the requirements for continued listing under the Nasdaq Listing Rules, the risk that Nasdaq may not grant the Company relief from delisting if necessary, and the risk that the Company may not ultimately meet applicable Nasdaq requirements if any such relief is necessary, among other risks and uncertainties, and actual results could differ materially from those anticipated in those forward-looking statements. The risks and uncertainties that may cause actual results to differ materially from the Company's current expectations are more fully described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 29, 2023, as amended, any subsequently filed Quarterly Reports on Form 10-Q, and its other reports, each as filed with the Securities and Exchange Commission. Except as required by law, the Company assumes no obligation to update any such forward-looking statement after the date of this report or to conform these forward-looking statements to actual results. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOCARDIA, INC.
BioCardia Frequently Asked Questions (FAQ)
When was BioCardia founded?
BioCardia was founded in 2002.
Where is BioCardia's headquarters?
BioCardia's headquarters is located at 125 Shoreway Road, San Carlos.
What is BioCardia's latest funding round?
BioCardia's latest funding round is Reverse Merger.
Who are the investors of BioCardia?
Investors of BioCardia include Tiger X Medical and OPKO Health.
Who are BioCardia's competitors?
Competitors of BioCardia include Zosano Pharma, Humanetics, United Biomedical, Vistagen, Alexza Pharmaceuticals and 11 more.
Compare BioCardia to Competitors
Orexo is a pharmaceutical company which focuses on identifying suboptimal therapeutic characteristics of existing products and developing more efficient and effective delivery methods for them.
Velbionanotech is designing drugs for various diseases such as Heart Disease, kidney stones, AIDS, Cancer, cosmetic generic products using a short fragment of DNA as a new type of drugs. These drugs are assembled in Nanochips and as nano particals for delivering in human body, which are affective in curing the sick/diseased and healing the injured. nVBN are working into New gene therapy procedures, DNA-based sensors, and other medical applications by using a new method developed to initiate and control chemical reactions on DNA strands. On the other hand silicon-based nanochips with itching and self-assembling techniques used to deliver drugs on the diseased molecules. The company are designing bionano products for the treatment of various diseases for Kidney stones,Gallbladder,Liver, Lungs,Heart etc mixing biology with traditional machinery. VBN Nanomedicine prepared for Heart disease, Galbladder, Liver, Kidney stones will have no side effect and it is safe to use since it is herbal. nn
Altea Therapeutics is using advanced delivery across the skin that aim to improve the efficacy, safety and compliance of drugs and vaccines.
Radius Health is a biopharmaceutical company focused on developing new therapeutics to treat osteoporosis and other women's health conditions. It is committed to the development of therapeutics for the osteoporosis market. The company's lead product candidate, BA058-SC, is in effect to reduce the risk of complications associated with osteoporosis, such as fractures and has a transdermal patch, BA058-TD, being developed as a short wear-time delivery vehicle intended to improve patient compliance with convenience and ease of use, as well as a product in development to treat symptoms associated with menopause. The company was founded in 2003 and is based in Boston, Massachusetts.
ncorporated in November 2005, with an asset value of about 10 million USD, Stemgen's labs are located in University of Bicocca - Milan with a currrent staff of 10 people including management and research staff. The Company has recently filed a PCT procedure covering the use of new potent anti-tumour molecules effective against glioblastoma multiforme (GBM). Each year up to 30.000 new cases of GBM are diagnosed in the world's seven largest healthcare markets and this specific market is still characterised by a high level of unmet therapeutic needs, despite the approval of several new products in the USA and Europe in recent years. The company's primary goal is to offer a therapy that will succed in covering this need. Once the company's new molecules are developed, licensing and strategic alliances policy will enable Stemgen to enter the GBM-therapy market.
Indena is a company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and cosmetics industries. Indena, a privately owned Italian company, has around 700 employees, including 10% dedicated to full-time research, aims to manage cultivation, manufacturing, and distribution operations in more than 40 countries throughout the world. The key to Indena's success is its research, covering: the screening of medicinal plants for their pharmacological benefits; the identification of new active principles; and the development of extraction and purification systems at the cutting-edge of industrial application. The phyto-chemical research is carried out in Indena's own Research Center in Settala, Italy. Indena also co-operates with the world's most prestigious universities and private research institutions in the biological assessment of safety and effectiveness up to clinical phase I. One of the main strategic objectives of the research is the development of new active principles for pharmaceutical applications. This is also an indispensable base for the health-food and cosmetics industries. In the pharmaceutical sector Indena is currently focusing on the development of anti-cancer treatments, following the successes of paclitaxel, as well as on anti-microbial and on anti-viral drugs. Also under study are active principles for the treatment of pathologies and dysfunction of the central nervous system, such as depression, anxiety, impotence, sleep disorders, and algesia. Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.